earnings estimate revisions
Search documents
Citizens (CIA) Tops Q2 Earnings Estimates
ZACKS· 2025-08-08 01:06
Group 1 - Citizens reported quarterly earnings of $0.13 per share, exceeding the Zacks Consensus Estimate of $0.04 per share, and up from $0.08 per share a year ago, representing an earnings surprise of +225.00% [1] - The company posted revenues of $62.68 million for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.16%, compared to $62.34 million in the same quarter last year [2] - Citizens has surpassed consensus EPS estimates only once in the last four quarters, indicating a mixed performance trend [2][6] Group 2 - The stock has gained approximately 4.5% since the beginning of the year, while the S&P 500 has increased by 7.9%, suggesting underperformance relative to the broader market [3] - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $64.07 million, and for the current fiscal year, it is $0.22 on revenues of $255.33 million [7] - The Insurance - Life Insurance industry is currently ranked in the top 20% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]
Goldman Sachs BDC (GSBD) Misses Q2 Earnings and Revenue Estimates
ZACKS· 2025-08-08 00:51
Company Performance - Goldman Sachs BDC reported quarterly earnings of $0.38 per share, missing the Zacks Consensus Estimate of $0.40 per share, and down from $0.57 per share a year ago, representing an earnings surprise of -5.00% [1] - The company posted revenues of $90.97 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 3.74%, and down from $108.62 million year-over-year [2] - Over the last four quarters, Goldman Sachs BDC has surpassed consensus EPS estimates only once and has not beaten consensus revenue estimates during the same period [2] Stock Performance - Goldman Sachs BDC shares have declined approximately 7.2% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The company's current Zacks Rank is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is $0.40 on revenues of $94.85 million, and for the current fiscal year, it is $1.60 on revenues of $381.25 million [7] - The outlook for the industry, specifically the Financial - SBIC & Commercial Industry, is currently in the bottom 42% of over 250 Zacks industries, which may impact the stock's performance [8]
indie Semiconductor, Inc. (INDI) Reports Q2 Loss, Beats Revenue Estimates
ZACKS· 2025-08-08 00:36
分组1 - indie Semiconductor reported a quarterly loss of $0.08 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.09 per share a year ago [1] - The company posted revenues of $51.63 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.26%, but down from $52.35 million year-over-year [2] - The stock has underperformed the market, losing about 10.4% since the beginning of the year, while the S&P 500 gained 7.9% [3] 分组2 - The current consensus EPS estimate for the coming quarter is -$0.05 on revenues of $56 million, and -$0.20 on revenues of $228.8 million for the current fiscal year [7] - The Zacks Industry Rank for Electronics - Semiconductors is in the bottom 31% of over 250 Zacks industries, indicating potential challenges for stock performance [8]
Skillz Inc. (SKLZ) Reports Q2 Loss, Tops Revenue Estimates
ZACKS· 2025-08-08 00:21
Company Performance - Skillz Inc. reported a quarterly loss of $1.12 per share, which was better than the Zacks Consensus Estimate of a loss of $1.34, representing an earnings surprise of +16.42% [1] - The company posted revenues of $27.37 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 20.05%, compared to revenues of $25.3 million a year ago [2] - Over the last four quarters, Skillz has surpassed consensus EPS estimates two times and topped consensus revenue estimates twice [2] Stock Movement and Outlook - Skillz shares have increased by approximately 40.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] - The future performance of Skillz's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$1.28 on revenues of $23.55 million, and for the current fiscal year, it is -$4.72 on revenues of $93.81 million [7] Industry Context - The Gaming industry, to which Skillz belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Skillz's stock performance [5]
nLight (LASR) Tops Q2 Earnings and Revenue Estimates
ZACKS· 2025-08-08 00:11
Company Performance - nLight reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of a loss of $0.09 per share, compared to a loss of $0.10 per share a year ago, representing an earnings surprise of +166.67% [1] - The company posted revenues of $61.74 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 12.11%, and showing an increase from year-ago revenues of $50.51 million [2] - nLight has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates four times during the same period [2] Stock Performance - nLight shares have increased approximately 87.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $54.52 million, and for the current fiscal year, it is -$0.28 on revenues of $215.83 million [7] Industry Outlook - The Electronics - Semiconductors industry, to which nLight belongs, is currently ranked in the bottom 31% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact nLight's stock performance [5]
Ouster, Inc. (OUST) Reports Q2 Loss, Beats Revenue Estimates
ZACKS· 2025-08-08 00:11
Company Performance - Ouster, Inc. reported a quarterly loss of $0.38 per share, better than the Zacks Consensus Estimate of a loss of $0.45, and an improvement from a loss of $0.53 per share a year ago, resulting in an earnings surprise of +15.56% [1] - The company posted revenues of $35.05 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 3.09% and showing a year-over-year increase from $26.99 million [2] - Over the last four quarters, Ouster has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Outlook - Ouster shares have increased approximately 88% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.44 on revenues of $36.3 million, and for the current fiscal year, it is -$1.71 on revenues of $143.4 million [7] - The estimate revisions trend for Ouster was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Electronics - Miscellaneous Components industry, to which Ouster belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]
Rocket Lab Corporation (RKLB) Reports Q2 Loss, Tops Revenue Estimates
ZACKS· 2025-08-08 00:01
Core Viewpoint - Rocket Lab Corporation reported a quarterly loss of $0.1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.07, marking an earnings surprise of -42.86% [1] Financial Performance - The company posted revenues of $144.5 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 6.98%, and showing an increase from $106.25 million in the same quarter last year [2] - Over the last four quarters, Rocket Lab has surpassed consensus revenue estimates four times, but has only exceeded EPS estimates once [2] Stock Performance - Rocket Lab shares have increased approximately 73.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] Future Outlook - The company's earnings outlook will be crucial for determining the sustainability of its stock price movement, with current consensus EPS estimates at -$0.07 for the upcoming quarter and -$0.26 for the current fiscal year [4][7] - The Zacks Rank for Rocket Lab is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Aerospace - Defense Equipment industry, to which Rocket Lab belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
ZACKS· 2025-08-08 00:01
Company Performance - Pacific Biosciences reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.18, and an improvement from a loss of $0.20 per share a year ago, resulting in an earnings surprise of +27.78% [1] - The company posted revenues of $39.77 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 9.06% and showing an increase from $36.01 million in the same quarter last year [2] - Over the last four quarters, Pacific Biosciences has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Pacific Biosciences shares have declined approximately 24.6% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $40.08 million, and for the current fiscal year, it is -$0.64 on revenues of $155.44 million [7] Industry Outlook - The Medical - Instruments industry, to which Pacific Biosciences belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact the stock's performance [5]
Veritone, Inc. (VERI) Reports Q2 Loss, Beats Revenue Estimates
ZACKS· 2025-08-07 23:56
Group 1 - Veritone, Inc. reported a quarterly loss of $0.18 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.19, and the same as the loss reported a year ago [1] - The company posted revenues of $24.01 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.98%, but down from $30.99 million year-over-year [2] - Veritone shares have declined approximately 29.9% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $28.45 million, and for the current fiscal year, it is -$0.58 on revenues of $108.01 million [7] - The Zacks Industry Rank indicates that the Technology Services sector is in the top 38% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]
Inogen (INGN) Reports Q2 Loss, Beats Revenue Estimates
ZACKS· 2025-08-07 23:56
Company Performance - Inogen reported a quarterly loss of $0.15 per share, better than the Zacks Consensus Estimate of a loss of $0.22, and an improvement from a loss of $0.24 per share a year ago [1] - The quarterly report represents an earnings surprise of +31.82%, following a previous surprise of +51.92% when the company posted a loss of $0.25 per share against an expected loss of $0.52 [2] - Inogen's revenues for the quarter ended June 2025 were $92.28 million, surpassing the Zacks Consensus Estimate by 1.76% and up from $88.76 million year-over-year [3] Market Performance - Inogen shares have declined approximately 31.3% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [4] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $92.91 million, and -$0.95 on revenues of $354.02 million for the current fiscal year [8] Industry Outlook - The Medical - Instruments industry, to which Inogen belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [9] - The performance of Inogen's stock may be influenced by the overall outlook for the industry, as top-ranked industries tend to outperform the bottom half by more than 2 to 1 [9]